Skip to main content
KBS_Icon_questionmark link-ico
Dr Aamir Ahmed

Dr Aamir Ahmed

  • Academics

Head of King’s Prostate Cancer Research Centre

Head of Stem Cell and Prostate Cancer Group.

Contact details


Aamir obtained his PhD from the University of Dundee where he also served as an Honorary Lecturer and Group Leader. He then joined Yale University as research faculty to work on ion channels. Aamir was awarded a Wellcome Trust Fellowship at the Department of Physiology, University College London, where he established his research group. This was followed by his appointment as the Head of Stem Cell Group at the Prostate Cancer Research Centre, also at the University College London. He joined the Centre for Stem Cells and Regenerative Medicine, King’s College London in January 2015.

Research interests

The objective of research in our group is to provide better treatment, diagnosis and prognosis for prostate cancer. We are interested, particularly, in the Wnt signalling network, a critical pathway during development and in disease. The focus of our research is the role Wnt signalling plays in prostate stem cells and prostate cancer. We employ a wide range of techniques to address fundamental questions regarding Wnt signalling and how this knowledge could be translated into better therapies and quantitative biomarkers of cancer. We have identified a class of drugs termed membrane potential regulating compounds (MPRCs) that are in clinical use to treat diseases other than cancer and could be re-tasked to treat prostate cancer. We use live calcium imaging, medium throughput and single-cell electrophysiology, immunocytochemistry, mouse in vivo and population-based, human drug data analytics to identify and develop MPRC that could be used to treat prostate cancer. We also use high-resolution, high-throughput tissue imaging combined with a gene, single-molecule RNA and protein immunochemistry and machine learning to identify meaningful, quantifiable, clinical biomarkers for better diagnosis and prognostication of prostate cancer.